MedWatch

Analyst foresaw Ambu flop: "I simply didn’t trust the information I got from the company"

Especially one analyst remained skeptical towards Ambu’s praise for its growth hope, the colonoscope SC210. “It’s okay to be optimistic but you still have to give the market correct information,” says the Carnegie analyst who was not particularly surprised by Ambu’s recent adjustment of the financial outlook and following share price decline.

Foto: PR, Carnegie

Monday last week, Danish medtech group Ambu presented a modified strategy that entailed downgrading of the financial guidance and shelving of the colonoscope SC210 that was supposed to be launched before Christmas.

The product was an important part of Ambu’s plans to reach next level as colonoscopies are far more common than the examinations Ambu’s existing products cover.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier